Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update.

Abstract:

:Despite continuous advances in myocardial revascularization procedures and intracoronary devices, patients with ischemic heart disease (IHD) still experience worse prognosis and poor quality of life (QoL). Indeed, chronic stable angina (CSA) is a common disease with a large burden on healthcare costs. Traditionally, CSA is interpreted as episodes of reversible myocardial ischemia related to the presence of stable coronary artery plaque causing myocardial demand/supply mismatch when myocardial oxygen consumption increases. Accordingly, revascularization procedures are performed with the aim to remove the flow limiting stenosis, whereas traditional medical therapy (hemodynamic agents) aims at reducing myocardial oxygen demands. However, although effective, none of these treatment strategies or their combination is either able to confer symptomatic relief in all patients, nor to reduce mortality. Failure to significantly improve QoL and prognosis may be attributed at least in part to this "restrictive" understanding of IHD. Despite for many years myocardial metabolic derangement has been overlooked, recently it has gained increased attention with the development of new pharmacological agents (metabolic modulators) able to influence myocardial substrate selection and utilization thus improving cardiac efficiency. Shifting cardiac metabolism from free fatty acids (FA) towards glucose is a promising approach for the treatment of patients with stable angina, independently of the underling disease (macrovascular and/or microvascular disease). In this sense cardiac metabolic modulators open the way to a "revolutionary" understanding of ischemic heart disease and its common clinical manifestations, where myocardial ischemia is no longer considered as the mere oxygen and metabolites demand/supply unbalance, but as an energetic disorder. Keeping in mind such an alternative approach to the disease, development of new pharmacological agents directed toward multiple metabolic targets is mandatory.

journal_name

Cardiovasc Drugs Ther

authors

Guarini G,Huqi A,Morrone D,Marzilli M

doi

10.1007/s10557-016-6677-y

subject

Has Abstract

pub_date

2016-08-01 00:00:00

pages

379-391

issue

4

eissn

0920-3206

issn

1573-7241

pii

10.1007/s10557-016-6677-y

journal_volume

30

pub_type

杂志文章,评审
  • Changes in urinary enzyme levels following the use of antihypertensive agents in patients with essential hypertension.

    abstract::When choosing antihypertensive agents for the treatment of hypertension, it is necessary to consider the predisposition of individuals to renal damage, which may be associated with the long-term effect of such agents. In this respect, this study examined the effect of two commonly used antihypertensive drugs (Brinerdi...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00879029

    authors: Obatomi DK,Mogbo SC,Anjorin FI,Jigam AA

    更新日期:1995-06-01 00:00:00

  • Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration.

    abstract::The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, high-frequency premature ventricular beats (PVB) (greater than 100/hr). A randomized, double-blind, cross...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00054209

    authors: Chimienti M,Regazzi MB,La Rovere MT,Salerno JA,Previtali M,Montericcio V,Rondanelli R,Montemartini C

    更新日期:1988-12-01 00:00:00

  • Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway.

    abstract::Endothelial dysfunction contributes to the initiation and development of hypertension. We previously found that simvastatin moderately decreases blood pressure in 2-kidney-2-clip (2k2c) renal hypertension, but the precise mechanisms are still unclear. The present study was designed to examine the protective actions of...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-011-6351-3

    authors: Zhang Z,Wang M,Xue SJ,Liu DH,Tang YB

    更新日期:2012-02-01 00:00:00

  • Mechanistic studies of AVE3085 against homocysteine in endothelial protection.

    abstract:PURPOSE:Homocysteine (Hcy) is an independent risk factor for cardiovascular diseases that impairs endothelial function. We investigated whether the impaired endothelial function can be restored by the eNOS transcription enhancer AVE3085 in porcine coronary arteries. The effects of AVE3085 against Hcy on eNOS-NO functio...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-013-6478-5

    authors: Yang Q,Xue HM,Underwood MJ,Yu CM

    更新日期:2013-12-01 00:00:00

  • Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study.

    abstract::The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction o...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/BF00877865

    authors: Zanchetti A

    更新日期:1995-08-01 00:00:00

  • Antiischemic effects of nicorandil during coronary angioplasty in humans.

    abstract::The present study was undertaken on 10 patients with angina undergoing percutaneous transluminal coronary angioplasty. The angioplasty procedure consisted of two successive 30-second balloon inflations at 5 minute intervals. After the first inflation, nicorandil (0.1 mg/kg) was given intravenously over a 2-minute peri...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00878473

    authors: Saito S,Mizumura T,Takayama T,Honye J,Fukui T,Kamata T,Moriuchi M,Hibiya K,Tamura Y,Ozawa Y

    更新日期:1995-03-01 00:00:00

  • Can Clinical and Functional Outcomes Be Improved with an Intelligent "Internet Plus"-Based Full Disease Cycle Remote Ischemic Conditioning Program in Acute ST-elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention? Rational

    abstract:BACKGROUND:Acute ST-elevation myocardial infarction (STEMI) is associated with a high incidence of complications as well as a considerable hospitalization rate and economic burden. Preliminary evidence suggests that remote ischemic conditioning (RIC) is a promising non-invasive intervention that may effectively and saf...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07022-9

    authors: Zheng Y,Reinhardt JD,Li J,Hu D,Lin S,Wang L,Dai R,Fan Z,Ding R,Chen L,Yuan L,Xu Z,Cheng Y,Yan C,Zhang X,Wang L,Zhang X,Teng M,Yu Q,Yin A,Lu X,i-RIC Trial Collaboration Group.

    更新日期:2020-06-30 00:00:00

  • Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.

    abstract:PURPOSE:To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. METHODS:We will enroll patients at ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10557-008-6121-z

    authors: Valgimigli M,Campo G,de Cesare N,Vranckx P,Hamon M,Angiolillo DJ,Sabatè M,Ferrari F,Furgieri A,Tumscitz C,Repetto A,Colangelo S,Meliga E,Kubbajeh M,Parrinello G,Percoco G,Ferrari R

    更新日期:2008-08-01 00:00:00

  • Amiodarone plus Ranolazine for Conversion of Post-Cardiac Surgery Atrial Fibrillation: Enhanced Effectiveness in Reduced Versus Preserved Ejection Fraction Patients.

    abstract:PURPOSE:Ranolazine (RAN) added to amiodarone (AMIO) has been shown to accelerate termination of postoperative atrial fibrillation (POAF) following coronary artery bypass surgery in patients without heart failure (HF). This study aimed to investigate if treatment efficacy with AMIO or AMIO + RAN differs between patients...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10557-018-6832-8

    authors: Simopoulos V,Hevas A,Hatziefthimiou A,Dipla K,Skoularigis I,Tsilimingas N,Aidonidis I

    更新日期:2018-12-01 00:00:00

  • Apoptosis in cardiac disease--what is it--how does it occur.

    abstract::This review will present a summary of a description of apoptotic pathways in the heart, followed by ways to measure it and the experimental and clinical evidence for the role of apoptosis in cardiac disease. An evaluation of the effectiveness of pharmacological and other therapeutic interventions in the prevention of ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1023/a:1013715704835

    authors: Neuss M,Crow MT,Chesley A,Lakatta EG

    更新日期:2001-11-01 00:00:00

  • Barriers to Beta-Blocker Use and Up-Titration Among Patients with Heart Failure with Reduced Ejection Fraction.

    abstract:PURPOSE:For patients with heart failure with reduced ejection fraction (HFrEF), guidelines recommend use of beta-blockers with gradual up-titration. However, many patients with HFrEF do not use beta-blockers and up-titration is rare. Our purpose was to identify and rank barriers to beta-blocker use and up-titration fro...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-017-6764-8

    authors: Levitan EB,Van Dyke MK,Loop MS,O'Beirne R,Safford MM

    更新日期:2017-12-01 00:00:00

  • A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.

    abstract::Piperanometozine (OPC-8212) is a new, orally effective inotropic agent. To evaluate the efficacy of this agent on systemic hemodynamics and clinical symptoms in patients with congestive heart failure, a multicenter study was performed. Thirty four patients with New York Heart Association (NYHA) functional classes II t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/BF02125470

    authors: Inoue M,Hori M,Yasuda H,Takishima T,Sugimoto T,Sasayama S,Sakurai T,Nonogi H,Kodama K,Kusukawa R

    更新日期:1987-08-01 00:00:00

  • Asialoerythropoietin exerts stronger angiogenic activity than erythropoietin via its binding affinity to tissue.

    abstract:PURPOSE:Although erythropoietin (EPO) is known to express angiogenic and cardioprotective effects, it also induces hypertension, polycythemia, and platelet activation, which may cause serious adverse effects in patients with cardiovascular diseases. We compared the angiogenic effects of EPO and its nonerythropoietic de...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-013-6438-0

    authors: Yanagawa T,Toba K,Kato K,Suzuki T,Minagawa S,Saigawa T,Ozawa T,Oda M,Takayama T,Hanawa H,Higuchi M,Saito H,Aizawa Y

    更新日期:2013-04-01 00:00:00

  • Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I.

    abstract::Calcium channel blockers are a group of drugs used for the treatment of hypertension. Carbonic anhydrase (CA) I detected in vascular smooth muscle and in other cells in the organism has a major role in the acid-base balance and in vascular processes. Our previous work has proven that verapamil inhibits CA activity by ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1007893207279

    authors: Puscas L,Gilau L,Coltau M,Pasca R,Domuta G,Baican M,Hecht A

    更新日期:2000-10-01 00:00:00

  • Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.

    abstract:PURPOSE:Platelets are essential for primary hemostasis; however, platelet activation also plays an important proinflammatory role. Inflammation promotes the development of cardiac fibrosis and heart failure induced by hypertension. In this study, we aimed to determine whether inhibiting platelet activation using clopid...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-013-6471-z

    authors: Jia LX,Qi GM,Liu O,Li TT,Yang M,Cui W,Zhang WM,Qi YF,Du J

    更新日期:2013-12-01 00:00:00

  • Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans.

    abstract::To compare the antiischemic effects of intracoronary administration of a beta blocker, atenolol, and of a calcium antagonist, nifedipine, on the clinical and electrocardiographic signs of myocardial ischemia induced by balloon occlusion of the coronary artery, we studied 32 consecutive patients undergoing routine PTCA...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00051147

    authors: Ghio S,De Servi S,Angoli L,Bramucci E,Eleuteri E,Raffaghello S,Specchia G

    更新日期:1992-06-01 00:00:00

  • Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models.

    abstract::Ranolazine, an inhibitor of the late current of the cardiac action potential (late I(Na)), is a well established clinical treatment for chronic angina. The late INa in cardiac myocytes also plays an important role in the pathophysiology of acute myocardial ischemia and reperfusion, and thus is a potential therapeutic ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-014-6548-3

    authors: Hale SL,Kloner RA

    更新日期:2014-10-01 00:00:00

  • Cholesterol confusion in primary prevention of coronary artery disease.

    abstract::Despite the impressive relation between an increased blood cholesterol and increased mortality from coronary artery disease and despite the persuasive results of cholesterol-lowering trials in secondary prevention, there are increasing reservations about the wisdom of lowering moderately raised blood cholesterol level...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 社论

    doi:10.1007/BF00878930

    authors: Opie LH

    更新日期:1993-11-01 00:00:00

  • Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.

    abstract:BACKGROUND:Heart failure (HF) is considered to be a prothrombotic condition and it has been suggested that coagulation factors contribute to maladaptive cardiac remodelling via activation of the protease-activated receptor 1 (PAR1). We tested the hypothesis that anticoagulation with the factor Xa (FXa) inhibitor apixab...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-06999-7

    authors: Yurista SR,Silljé HHW,Nijholt KT,Dokter MM,van Veldhuisen DJ,de Boer RA,Westenbrink BD

    更新日期:2020-05-26 00:00:00

  • Postinfarct heart failure: role of diuretic therapy.

    abstract::There can be no doubt that ACE inhibitors prolong survival in patients with a low ejection fraction. There is no evidence whether or not diuretics have the same effect. The pathophysiology of asymptomatic patients with poor left ventricular function differs from that of patients with the clinical syndrome of heart fai...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00877716

    authors: Hampton JR

    更新日期:1993-12-01 00:00:00

  • Postconditioning in reperfusion injury: a status report.

    abstract::Early reperfusion after an organ ischemia is essential to salvage tissue from eventual death. However, abundant evidence suggests that reperfusion also elicits pathophysiological changes responsible for additional tissue injury after restoration of blood flow. Postconditioning (Postcon) defined as rapid sequential int...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-010-6240-1

    authors: Zhao ZQ

    更新日期:2010-06-01 00:00:00

  • Amlodipine and physiological responses to brisk exercise in healthy subjects.

    abstract::Recent studies have questioned the safety of calcium antagonists in general, and short-acting dihydropyridine derivatives in particular. Reasons include excessive catecholamine stimulation after stress. We therefore wanted to assess whether amlodipine, a second generation dihydropyridine with a prolonged plasma half-l...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1007875603969

    authors: Stankovic S,Panz V,Klug E,Di Nicola G,Joffe BI

    更新日期:1999-11-01 00:00:00

  • The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs.

    abstract::The direct myocardial protective effects of intracoronary infusions of cromakalim and pinacidil were determined in an anesthetized canine model of coronary occlusion and reperfusion. The left circumflex coronary artery was occluded for 90 minutes and reperfused for 5 hours, at which time the infarct size was determine...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01857755

    authors: Grover GJ,Dzwonczyk S,Parham CS,Sleph PG

    更新日期:1990-04-01 00:00:00

  • Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.

    abstract:PURPOSE:This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting. METHODS:We constructed a Markov model to project the lifetime direct medical costs and quality-adjusted life-years of both the...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07059-w

    authors: Lee MC,Liao CT,Toh HS,Chou CC,Chang WT,Chen ZC,Wu WS,Yu T,Strong C

    更新日期:2020-09-10 00:00:00

  • The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig.

    abstract::The effects of oral zofenopril pretreatment were investigated in a chronic closed-chest pig model of ischemia and reperfusion. Pigs (25-35 kg) were pretreated orally with zofenopril (15 mg/day) on the 2 days prior to ischemia, which was evoked by the inflation of a catheter balloon in the left anterior descending coro...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01856557

    authors: Tio RA,de Langen CD,de Graeff PA,van Gilst WH,Bel KJ,Wolters KG,Mook PH,van Wijngaarden J,Wesseling H

    更新日期:1990-06-01 00:00:00

  • The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

    abstract::Despite the fact that beta blockers were introduced into clinical practice 25 years ago, new beta blockers with differing kinetic and dynamic profiles continue to be developed and marketed. This overview assesses some of the more extensively studied agents from the point of view of proof of utility and the validity of...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03029726

    authors: Fitzgerald JD

    更新日期:1991-06-01 00:00:00

  • Torsades de pointes: arrhythmia, syndrome, or chimera?

    abstract::Although torsades de pointes is not a tightly demarcated entity, the diagnosis has important clinical implications. The concept should be retained. ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF03029821

    authors: Millar RN

    更新日期:1991-02-01 00:00:00

  • Mitochondrial-Shaping Proteins in Cardiac Health and Disease - the Long and the Short of It!

    abstract::Mitochondrial health is critically dependent on the ability of mitochondria to undergo changes in mitochondrial morphology, a process which is regulated by mitochondrial shaping proteins. Mitochondria undergo fission to generate fragmented discrete organelles, a process which is mediated by the mitochondrial fission p...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-016-6710-1

    authors: Ong SB,Kalkhoran SB,Hernández-Reséndiz S,Samangouei P,Ong SG,Hausenloy DJ

    更新日期:2017-02-01 00:00:00

  • Mechanisms of nitrate tolerance: a review.

    abstract::With the increased use of long-acting nitroglycerin preparations, there has been greater recognition of the problem of nitrate tolerance. In recent years extensive research has broadened our understanding of the mechanisms of nitroglycerin action and the mechanisms of drug attenuation. This paper reviews the current s...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF01857640

    authors: Katz RJ

    更新日期:1990-02-01 00:00:00

  • Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.

    abstract:PURPOSE:To evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against ischemia-reperfusion injury. METHODS:Human cardiomyocytes (HCMs), cardiomyocytes from cardiac-specific PPARγ knockout (MCM-PPARγ (CKO) ) or wild type (MCM-WT) mice were incubated with different ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-016-6650-9

    authors: Qian J,Chen H,Birnbaum Y,Nanhwan MK,Bajaj M,Ye Y

    更新日期:2016-04-01 00:00:00